Inclusive of all taxes
Altanib Nova 400mg Tablet is a branded generic formulation of Imatinib Mesylate, a potent tyrosine kinase inhibitor specifically designed for targeted cancer therapy. This oncology medication plays a critical role in managing and treating various blood cancers and gastrointestinal tumors by selectively inhibiting abnormal tyrosine kinases like BCR-ABL, c-KIT, and PDGFR. The tablet effectively disrupts cancer cell proliferation and promotes apoptosis, significantly improving survival rates in conditions such as Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (ALL), Gastrointestinal Stromal Tumors (GISTs), and other hematologic malignancies. Altanib Nova 400mg is manufactured under stringent quality controls, ensuring precision dosing and safety for oral administration. It is suitable for use as first-line therapy and is typically prescribed at doses ranging from 400mg to 600mg per day, depending on the diagnosis and disease phase. The drug is available in bottles or blister packs of 30 or 60 tablets, facilitating convenient distribution for oncology centers and specialized healthcare providers. Proper storage guidelines must be followed to maintain drug efficacy, including protection from moisture, light, and temperatures above 30°C. This medication requires administration under strict medical supervision with necessary monitoring of blood parameters and organ functions to manage potential side effects such as edema, nausea, and muscle cramps. Altanib Nova is an essential pharmaceutical product for cancer treatment portfolios and is widely supplied through oncology-focused exporters from India, meeting global standards for cancer therapeutics.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Imatinib Mesylate |
| Strength | 400 mg per tablet |
| Therapeutic Class | Tyrosine Kinase Inhibitor (TKI) - Targeted Oncology Therapy |
| Indications | Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (ALL), Gastrointestinal Stromal Tumors (GISTs), Myelodysplastic/Myeloproliferative Diseases (MDS/MPD), Hypereosinophilic Syndrome (HES), Chronic Eosinophilic Leukemia (CEL), Dermatofibrosarcoma Protuberans (DFSP) |
| Dosage Form | Oral Tablet |
| Packaging | Bottle or blister pack of 30 or 60 tablets |
| Administration | Oral, to be taken with food and water |
| Storage Conditions | Below 30°C, protect from moisture and light |
| Manufacturer Type | Branded generic from oncology-focused pharmaceutical manufacturers |
| Side Effects | Edema, nausea, muscle cramps, rash; requires medical supervision |
| Attributes | Description |
|---|---|
| Chemical Name | Imatinib Mesylate |
| Molecular Weight | 589.7 g/mol |
| Mechanism of Action | Selective inhibition of BCR-ABL, c-KIT, and PDGFR tyrosine kinases |
| Pharmacological Class | Targeted anti-cancer agent |
| Typical Dosage | 400mg to 600mg once daily or as prescribed |
| Administration Route | Oral |
| Indications Specificity | Targets diseases characterized by tyrosine kinase gene mutations or activation |
| Storage Requirements | Store below 30°C; keep away from moisture and light |
| Packaging Details | Available in 30 or 60 tablet bottles or blisters |
| Monitoring Requirements | Regular blood counts, liver and kidney function tests |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Altanib Nova 400mg contains Imatinib Mesylate, which selectively inhibits specific tyrosine kinase enzymes such as BCR-ABL, c-KIT, and PDGFR. These kinases are involved in the abnormal growth signaling pathways of both hematologic malignancies like CML and solid tumors such as Gastrointestinal Stromal Tumors (GIST), making this drug effective across these cancer types.
Typically, the dose ranges from 400mg once daily for newly diagnosed chronic phase CML to up to 600mg or more for advanced phases or GIST. The prescribing oncologist determines the exact dosage based on disease severity, patient tolerance, and response during treatment.
The tablets must be stored below 30°C, protected from moisture and direct light exposure. Proper storage in original packaging like blister packs or sealed bottles preserves the chemical stability and therapeutic properties of Imatinib.
Yes, patients undergoing treatment must have regular monitoring of blood counts, liver function tests, and renal parameters due to possible side effects like edema, hepatic abnormalities, or renal impairment. This ensures the safe administration of the drug.
It is recommended to take the tablet with food and a large glass of water to minimize gastrointestinal irritation and maximize absorption.
Country Of Origin: India
Product Name: Altanib Nova 400mg Tablet
Generic Name:
Imatinib Mesylate (400mg)
Manufacturer:
(Usually produced by various oncology-focused companies; “Altanib Nova” is a branded generic)
Therapeutic Category:
Oncology / Targeted Therapy (Tyrosine Kinase Inhibitor)
Product Description:
Altanib Nova 400mg Tablet contains Imatinib Mesylate, a targeted anti-cancer medicine belonging to the class of tyrosine kinase inhibitors (TKIs). It works by blocking abnormal proteins that signal cancer cells to multiply, thereby slowing or stopping cancer progression.
It is considered a revolutionary therapy for certain types of blood cancers and gastrointestinal tumors.
Indications:
• Chronic Myeloid Leukemia (CML) – newly diagnosed, chronic phase, accelerated phase, or blast crisis
• Acute Lymphoblastic Leukemia (ALL) (Philadelphia chromosome-positive)
• Gastrointestinal Stromal Tumors (GISTs)
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)
• Hypereosinophilic Syndrome (HES) & Chronic Eosinophilic Leukemia (CEL)
• Dermatofibrosarcoma Protuberans (DFSP)
Mechanism of Action:
Imatinib selectively inhibits BCR-ABL tyrosine kinase, the abnormal protein produced by the Philadelphia chromosome in CML, and also inhibits other oncogenic kinases (such as c-KIT and PDGFR).
This prevents cancer cell proliferation and induces apoptosis (programmed cell death).
Dosage & Administration:
• Usual dose: 400mg to 600mg once daily, or as prescribed.
• For GIST or advanced CML, higher doses may be required.
• To be taken with food and a large glass of water to reduce GI irritation.
Key Benefits:
• First-line therapy for CML and GIST.
• Improves survival rates significantly in leukemia patients.
• Oral administration (convenient for patients).
Packaging:
• Bottle/Blister pack of 30 or 60 tablets (400mg each).
Storage:
• Store below 30°C.
• Protect from moisture and light.
• Keep out of reach of children.
Important Notes:
• For use under strict medical supervision only.
• Regular monitoring of blood counts, liver function, and renal function is required.
• Not recommended during pregnancy or breastfeeding.
• Patients may experience side effects such as edema, nausea, muscle cramps, or rash.
ONCOLOGY EXPORTERS FROM INDIA
Oncology byulk exporter from India
Oncology products supplier exporters
Exporters of pharmaceutical products
Melizza Lifescience
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
